Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic Impairment

Elvitegravir (EVG), an HIV strand transfer integrase inhibitor, is metabolized primarily via cytochrome P450 3A4 (CYP3A) and secondarily via glucuronidation. The pharmacokinetics (PK) and safety of cobicistat (COBI)-boosted EVG (EVG/co) were evaluated in subjects with impaired liver function. The en...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Custodio, Joseph M., Rhee, Martin, Shen, Gong, Ling, Kah Hiing J., Kearney, Brian P., Ramanathan, Srinivasan
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2014
Assuntos:
Clinical Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3993274/
https://ncbi.nlm.nih.gov/pubmed/24550332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02180-13
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados